Research programme: peptide therapeutics - Rhythm Pharmaceuticals
Alternative Names: BIM 22103Latest Information Update: 27 Dec 2022
At a glance
- Originator Ipsen
- Developer Ipsen; Rhythm
- Class Obesity therapies; Peptides
- Mechanism of Action Melanocortin type 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity
Most Recent Events
- 27 Dec 2022 Preclinical development in Obesity is ongoing in USA and France (Parenteral) (Rhythm Pharmaceuticals pipeline, December 2022)
- 09 Jan 2018 Preclinical development in Obesity is ongoing in USA (Parenteral)
- 09 Jan 2018 Rhythm Pharmaceuticals and WuXi NextCODE agree co-develop anti-obesity therapeutics for Obesity